DK1200117T3 - Behandling med lipoprotein-lipase (LPL) variant - Google Patents

Behandling med lipoprotein-lipase (LPL) variant

Info

Publication number
DK1200117T3
DK1200117T3 DK00943499T DK00943499T DK1200117T3 DK 1200117 T3 DK1200117 T3 DK 1200117T3 DK 00943499 T DK00943499 T DK 00943499T DK 00943499 T DK00943499 T DK 00943499T DK 1200117 T3 DK1200117 T3 DK 1200117T3
Authority
DK
Denmark
Prior art keywords
lpl
lipoprotein
lipase
treatment
variant treatment
Prior art date
Application number
DK00943499T
Other languages
English (en)
Inventor
Katherine Julia Diane Excoffon
Michael R Hayden
John J P Kastelein
Original Assignee
Univ British Columbia
Amsterdam Molecular Therapeutics Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ British Columbia, Amsterdam Molecular Therapeutics Bv filed Critical Univ British Columbia
Application granted granted Critical
Publication of DK1200117T3 publication Critical patent/DK1200117T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01034—Lipoprotein lipase (3.1.1.34)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
DK00943499T 1999-06-24 2000-06-23 Behandling med lipoprotein-lipase (LPL) variant DK1200117T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99202048 1999-06-24
PCT/CA2000/000762 WO2001000220A2 (en) 1999-06-24 2000-06-23 Lipoprotein lipase (lpl) variant therapeutics

Publications (1)

Publication Number Publication Date
DK1200117T3 true DK1200117T3 (da) 2008-11-17

Family

ID=8240356

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00943499T DK1200117T3 (da) 1999-06-24 2000-06-23 Behandling med lipoprotein-lipase (LPL) variant

Country Status (12)

Country Link
US (1) US20110201673A1 (da)
EP (1) EP1200117B1 (da)
JP (1) JP5095894B2 (da)
AT (1) ATE404217T1 (da)
AU (1) AU5799200A (da)
CA (1) CA2370081C (da)
CY (1) CY1108511T1 (da)
DE (1) DE60039880D1 (da)
DK (1) DK1200117T3 (da)
ES (1) ES2311464T3 (da)
PT (1) PT1200117E (da)
WO (1) WO2001000220A2 (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005015687D1 (de) * 2004-03-02 2009-09-10 Cellectar Inc Phospholipid-analoga für die behandlung von krebs
KR20070057712A (ko) * 2004-06-21 2007-06-07 아카데미쉬 지에켄후이스 비즈 드 유니버시테이트 반 암스테르담 비알코올성 지방 간염(ｎａｓｈ)의 치료 방법
PL1945779T3 (pl) 2005-10-20 2013-08-30 Uniqure Ip Bv Ulepszone wektory AAV produkowane w komórkach owadzich
KR101589259B1 (ko) 2006-06-21 2016-02-01 유니큐어 아이피 비.브이. 곤충세포 내 ａａｖ의 생산에 유용한 ａａｖ-ｒｅｐ78의 번역을 위한 변형된 개시 코돈을 갖는 벡터
MX2010000944A (es) 2007-07-26 2010-08-31 Amsterdam Molecular Therapeutics Bv Vectores baculovirales que comprenden secuencias de codificacion repetida con deformaciones diferenciales en codones.
WO2009030254A1 (en) * 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
EP2432497A1 (en) * 2009-05-18 2012-03-28 Amsterdam Molecular Therapeutics (AMT) IP B.V. Use of lipoprotein lipase (lpl) in therapy
DK2440253T3 (da) 2009-06-12 2020-07-20 Cellectar Inc Alkylphospholipidforbindelser til behandling af cancer og billeddannelse og detektering af cancerstamceller
EP2545165B1 (en) 2010-03-11 2020-07-29 uniQure IP B.V. Mutated rep encoding sequences for use in aav production
WO2011122950A1 (en) 2010-04-01 2011-10-06 Amsterdam Molecular Therapeutics (Amt) Ip B.V. Monomeric duplex aav vectors
WO2013119880A1 (en) 2012-02-07 2013-08-15 Global Bio Therapeutics Usa, Inc. Compartmentalized method of nucleic acid delivery and compositions and uses thereof
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
EA201690675A1 (ru) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
MX2016011585A (es) 2014-03-10 2016-11-29 Uniqure Ip Bv Vectores aav mejorados adicionales producidos en celulas de insecto.
MA41035A (fr) * 2014-08-19 2017-08-15 Shire Human Genetic Therapies Lipoprotéine lipase pour le traitement d'affections liées à une hypertriglycéridémie, y compris la pancréatite aiguë
US20190390181A1 (en) * 2016-05-18 2019-12-26 Modernatx, Inc. Polynucleotides Encoding Lipoprotein Lipase for the Treatment of Hyperlipidemia
CA3045551A1 (en) 2016-12-16 2018-06-21 Uniqure Ip B.V. Immunoadsorption
WO2019011893A1 (en) 2017-07-10 2019-01-17 Uniqure Ip B.V. MEANS AND METHODS OF GENE THERAPY BY ASSOCIATED ADENO VIRUS (AAV) IN HUMANS
EP3655538A1 (en) 2017-07-20 2020-05-27 uniQure IP B.V. Improved aav capsid production in insect cells
CN111527201A (zh) 2017-12-29 2020-08-11 优尼科Ip有限公司 修饰的病毒载体及其制备和使用方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2188675A1 (en) * 1994-04-11 1995-10-19 Savio L. C. Woo Compositions and methods for gene therapy to treat disease
US5658729A (en) * 1994-10-11 1997-08-19 The University Of British Columbia Method, reagent and kit for evaluating susceptibility to premature atherosclerosis

Also Published As

Publication number Publication date
CY1108511T1 (el) 2014-04-09
AU5799200A (en) 2001-01-31
EP1200117A2 (en) 2002-05-02
ES2311464T3 (es) 2009-02-16
CA2370081C (en) 2014-06-03
US20110201673A1 (en) 2011-08-18
JP2003503355A (ja) 2003-01-28
PT1200117E (pt) 2008-11-26
WO2001000220A3 (en) 2001-07-12
ATE404217T1 (de) 2008-08-15
WO2001000220A2 (en) 2001-01-04
CA2370081A1 (en) 2001-01-04
JP5095894B2 (ja) 2012-12-12
DE60039880D1 (en) 2008-09-25
EP1200117B1 (en) 2008-08-13

Similar Documents

Publication Publication Date Title
CY1108511T1 (el) Θεραπευτικες παραλλαγες της λιποπρωτεϊνικης λιπασης (lpl)
DE60235761D1 (de) Isoform des vegfs
ATE376591T1 (de) Neisseria meningitidis antigene und zusammenstellungen
EP1918300A3 (en) Peptide-based immunization therapy for treatment of atherosclerosis
DK0966465T3 (da) Inhibitorer af IMPDH-enzymer
DE60032367D1 (de) Aktivierbare rekombinante neurotoxine
DE50113396D1 (de) System zur gezielten Deformation von optischen Elementen
DE69834267D1 (de) Gentherapeutische verfahren zur bereitstellung von apolipoprotein a-i agonisten sowie deren verwendung zur behandlung dyslipidämischer erkrankungen
ATE232873T1 (de) Phosphonsaürederivate als ptp-1b-inhibitoren
CY1112324T1 (el) Φαρμακευτικες συνθεσεις αναστολεων της πρωτεϊνης μεταφορας εστερων χοληστερολης (cετρ)
DE69636453D1 (de) Modulation der aktivität des cholesteryl-ester-transfer-proteins (cetp)
ATE300619T1 (de) Humane checkpointkinase, hcds1, zusammensetzungen und verfahren
DE60023860D1 (de) Verfahren zur herstellung von rekombinanten peptiden
DK1908772T3 (da) Polypeptider og polynucleinsyrer af phorphorymonas gingivalis
EA200000520A1 (ru) 2-АРИЛ-3-АРОИЛБЕНЗО[b]ТИОФЕНЫ, ПОЛЕЗНЫЕ ДЛЯ ЛЕЧЕНИЯ СИНДРОМА ЭСТРОГЕННОЙ НЕДОСТАТОЧНОСТИ
ATE356212T1 (de) O-fukosyltransferase
DE69826717D1 (de) Target zur behandlung von atherosklerose, fettleibigkeit und diabetis typ ii
WO2002062964A3 (en) Ap1 amine oxidase variants
ATE375390T1 (de) G-protein-gekoppelter rezeptor-ähnliche proteine
SE9604439D0 (sv) New receptor
WO2001044514A3 (en) Methods and compositions for identifying morphogenic protein analogs using morphogenic protein responsive inhibitory elements
ATE427961T1 (de) Mit fettzellendifferenzierung assoziiertes gen und protein